About Integrated Micro-Chromatography Systems, Inc. At Integrated Micro-Chromatography Systems (IMCS), we strive to address the growing needs of clinical and research laboratories through advanced technologies that increase testing efficiency. IMCS products help to drive the future of precision medicine. We understand the importance of accuracy, which is why we are committed to delivering products that consistently provide fast, reliable results. Company History Integrated Micro-Chromatography Systems, Inc (IMCS) was founded in January 2013 by three scientists from the University of South Carolina. IMCS designs, develops, manufactures, and distributes next-generation recombinant proteins and chromatography consumables to clinical and forensic toxicology laboratories, academic research facilities, US government agencies, and health science companies worldwide. The company has two product lines: IMCSzyme® and IMCStips®. The industry disrupting IMCSzyme is a genetically modified enzyme primarily used by clinical, forensic, and pain care laboratories for the drug screening and analysis of urine and other biological samples. IMCStips are advanced micro-chromatography products centered around patented dispersive solid-phase extraction (dSPE) technology containing loosely packed resin for faster biochemical purification processes. IMCStips are utilized by academic laboratories and health science companies for purifying new proteins, antibodies and enzymes, as part of drug target discovery and validation, drug development, drug screening, and drug manufacturing. Recently, IMCS was awarded NIH SBIR and STTR funds to manufacture various glycosyltransferases to leverage the company’s advanced manufacturing and research capabilities to expand the synthesis of glycosphingolipids and sialoglycans. This expansion provides IMCS with new product lines and delivers critically needed biological reagents that were not previously available to the scientific community.